Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Ottawa

$31,000.00

Dedifferentiation induced by newt extract

EF 2016-17

Résumé
The newt, Notophthalmus viridescens, is an amphibian that can regenerate appendages, eye structures and many vital organs. During the regeneration process, tissues at the injury site revert from their differentiated form into an embryonic-like state. This dedifferentiation process generates a population of proliferating progenitor cells that can then redifferentiate into the multiple tissues of the regenerated structure. A better understanding of the dedifferentiation process would have tremendous implications for our understanding of regenerative potential in both newts and higher vertebrates. Dedifferentiation capabilities in both newts and mammals have been extensively studied in vitro using muscle-derived cell lines. Studies with the newt A1 muscle cell line have shown that mature differentiated A1 cells can re-enter the cell cycle following treatment with foetal bovine serum (FBS). Mammalian differentiated muscle cells do not possess this capability and remain post-mitotic. However, mouse C2C12 myotubes can re-enter the cell cycle following treatment with extract derived from a regenerating newt limb, suggesting that mammalian cells still possess dedifferentiation capabilities but may not have the appropriate triggers to initiate the response. We have recently shown that primary mouse myotubes do not re-enter the cell cycle following extract treatment. Thus it appears that C2C12 cells possess less dedifferentiation capability than newt cells but more than primary muscle cells. The aim of this proposal is to study the dedifferentiation process in newt and mammalian muscle cells, to determine the genetic differences that govern their abilities to dedifferentiate, and to ultimately improve the dedifferentiation process in mammalian cells. We have isolated another newt muscle cell line (called A2). Unlike A1 cells, A2 myotubes do not respond to FBS treatment by re-entering the cell cycle. In Aim 1, we will characterize the dedifferentiation process in newt A1 and A2 cells. By comparing the transcriptomes of A1 and A2 cells, we will determine which mutations allow cell cycle re-entry. We will also further characterize the dedifferentiation process and determine if cell death (caspase activation) and p53 activation are involved. In Aim 2, we will characterize the dedifferentiation process in mammalian C2C12 and primary muscle cells. Since C2C12 cells respond to extracts by fragmenting and re-entering the cell cycle, whereas primary muscle cells only fragment, we will determine the differences between the two cell types and assess whether cell cycle genes and apoptotic genes are involved in the responses of the cells to extract. Ultimately, a better understanding of the differences in dedifferentiation capability between newt cells and mammalian cells may help us to better understand the regenerative capability of newts and to improve regenerative ability in mammalian cells.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2016-05654
Name nom
Tsilfidis, Catherine
Department département
Cellular and Molecular Medicine - Médecine cellulaire et moléculaire
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
31000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5105
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell differentiation
Research subject fr
Différenciation cellulaire
Partie
1
Nb partie
5
Application title
Dedifferentiation induced by newt extract
Keyword
NSERC
Application summary
The newt, Notophthalmus viridescens, is an amphibian that can regenerate appendages, eye structures and many vital organs. During the regeneration process, tissues at the injury site revert from their differentiated form into an embryonic-like state. This dedifferentiation process generates a population of proliferating progenitor cells that can then redifferentiate into the multiple tissues of the regenerated structure. A better understanding of the dedifferentiation process would have tremendous implications for our understanding of regenerative potential in both newts and higher vertebrates. Dedifferentiation capabilities in both newts and mammals have been extensively studied in vitro using muscle-derived cell lines. Studies with the newt A1 muscle cell line have shown that mature differentiated A1 cells can re-enter the cell cycle following treatment with foetal bovine serum (FBS). Mammalian differentiated muscle cells do not possess this capability and remain post-mitotic. However, mouse C2C12 myotubes can re-enter the cell cycle following treatment with extract derived from a regenerating newt limb, suggesting that mammalian cells still possess dedifferentiation capabilities but may not have the appropriate triggers to initiate the response. We have recently shown that primary mouse myotubes do not re-enter the cell cycle following extract treatment. Thus it appears that C2C12 cells possess less dedifferentiation capability than newt cells but more than primary muscle cells. The aim of this proposal is to study the dedifferentiation process in newt and mammalian muscle cells, to determine the genetic differences that govern their abilities to dedifferentiate, and to ultimately improve the dedifferentiation process in mammalian cells. We have isolated another newt muscle cell line (called A2). Unlike A1 cells, A2 myotubes do not respond to FBS treatment by re-entering the cell cycle. In Aim 1, we will characterize the dedifferentiation process in newt A1 and A2 cells. By comparing the transcriptomes of A1 and A2 cells, we will determine which mutations allow cell cycle re-entry. We will also further characterize the dedifferentiation process and determine if cell death (caspase activation) and p53 activation are involved. In Aim 2, we will characterize the dedifferentiation process in mammalian C2C12 and primary muscle cells. Since C2C12 cells respond to extracts by fragmenting and re-entering the cell cycle, whereas primary muscle cells only fragment, we will determine the differences between the two cell types and assess whether cell cycle genes and apoptotic genes are involved in the responses of the cells to extract. Ultimately, a better understanding of the differences in dedifferentiation capability between newt cells and mammalian cells may help us to better understand the regenerative capability of newts and to improve regenerative ability in mammalian cells.